Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00142298 · ClinicalTrials.gov registry record · Phase 3
Telbivudine in Adults Previously Treated in Idenix-Sponsored Telbivudine Studies
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,869
- Enrollment target
NCT00142298 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 1,869 participants.
The verdict
NCT00142298, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,869 participants
- Enrollment target
Study Summary
This trial is being conducted as an open-label, extended-term study for patients with chronic hepatitis B who have previously completed an Idenix-sponsored trial with telbivudine.
Interventions
- DRUG Telbivudine (LdT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,869 participants |
| Start Date | 2005-03 |
| Est. Completion | 2009-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00142298
The ClinicalTrials.gov registry entry for NCT00142298 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,869 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Telbivudine (LdT) is the first listed.
NCT00142298 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00142298 about?
NCT00142298 is a clinical study titled "Telbivudine in Adults Previously Treated in Idenix-Sponsored Telbivudine Studies". This trial is being conducted as an open-label, extended-term study for patients with chronic hepatitis B who have previously completed an Idenix-sponsored trial with telbivudine.
What is the current status of trial NCT00142298?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,869 participants. The study started on 2005-03. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00142298?
The interventions under investigation include: Telbivudine (LdT) (DRUG).
Who is sponsoring clinical trial NCT00142298?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.